Quarterly ResultAug 5, 2026, 07:05 AM
Royalty Pharma Raises 2026 Guidance, Q2 Portfolio Receipts Up 6%
AI Summary
Royalty Pharma plc reported strong financial results for the second quarter of 2026, with Portfolio Receipts increasing by 6% to $773 million and Royalty Receipts growing 14% to $768 million. The company raised its full-year 2026 Portfolio Receipts guidance to $3,400 million to $3,500 million, marking the second guidance increase this year. This performance was supported by significant capital deployment of over $1 billion year-to-date, including the acquisition of a royalty on AstraZeneca’s cliramitug, and positive regulatory updates for several portfolio products.
Key Highlights
- Raised full-year 2026 Portfolio Receipts guidance to $3,400M-$3,500M.
- Q2 2026 Portfolio Receipts increased 6% to $773M.
- Q2 2026 Royalty Receipts grew 14% to $768M.
- Net cash provided by operating activities was $728M in Q2 2026.
- Capital Deployment reached $1.1B year-to-date as of August 4, 2026.
- Acquired royalty on AstraZeneca’s cliramitug for up to $425M.
- FDA accepted NDA for daraxonrasib and approved Trodelvy, Jideytro, Imdelltra.
Price Impact
More from RPRX